Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report

Erin Kelty, V. Martyn, G. O'Neil, Gary Hulse

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Idiopathic hypersomnia (IH) is a rare sleep disorder, recently hypothesized to be related to the production of a molecule that facilitates the binding of gamma-aminobutyric acid (GABA) to the GABA receptor. This paper reports on the treatment of a patient with IH who was treated with a 96-hour continuous low dose (4 mg/day) infusion of a benzodiazepine antagonist, flumazenil, followed by a slow-release flumazenil implant. The use of flumazenil mitigated the patient's IH symptoms including excessive daytime sleepiness, sleep drunkenness and self-reported cognitive problems. The case both provides a possible treatment and system for short (subcutaneous (SC) administration) and longer term (implant) flumazenil delivery. Current data supports the need for further research into the use of flumazenil for the treatment of IH and to develop long term flumazenil delivery systems. © The Author(s) 2014.
    Original languageEnglish
    Pages (from-to)703-706
    JournalJournal of Psychopharmacology
    Volume28
    Issue number7
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report'. Together they form a unique fingerprint.

  • Cite this